Adagio Medical Holdings, Inc.

Adagio Medical is a medical device company that develops and commercializes catheter-based systems for treating cardiac arrhythmias, focusing primarily on ventricular tachycardia. Its core offerings include the vCLAS Cryoablation System and Ultra-Low Temperature Ablation console, which use pressurized, near-critical liquid nitrogen to create deep, durable lesions in cardiac tissue without fluid irrigation. The company also develops pulsed field cryoablation technologies combining ultracold cryoablation with pulsed field energy. These medical solutions are designed for electrophysiologists, cardiac catheterization laboratories, and hospital ablation centers treating patients affected by ventricular tachycardia, structural heart disease, and atrial fibrillation.

The company operates internationally through regulatory clinical trial networks and commercial authorization pathways. Its clinical studies encompass dozens of investigative medical centers across the United States, Canada, and the European Union. Its initial cryoablation system holds European CE Mark approval and investigational clearance in the United States, supported by a global intellectual property portfolio. The company's headquarters are not stated in the provided text.

Summary of the business section of Adagio Medical's latest annual report, written by StockData.

“As of December 31, 2025, we had 41 full-time employees, located in the U.S.”